Syncona : Anaveon announces publication of ANV419 Phase I data in The Journal for ImmunoTherapy of Cancer -December 14, 2023 at 04:04 am EST
ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile Anaveon, a clinical stage, immuno-oncology company, today announced the publication of...
Source: marketscreener.com